Committee on Public Health
Bill Summary

Bill No.	H2472/S1497
Title:	*An Act protecting patient safety regarding non-FDA approved drugs*
Sponsor:	Representative Kathleen R. LaNatra/Senator John J. Cronin
Committee:	Public Health
Hearing Date:	June 11, 2025
Similar Matters:	S1497
Prior History:	New File
Reporting Deadline:	August 10, 2025
Current Law:	None

Summary:

Prohibits retail pharmacies from reselling medications that a pharmacist has compounded for a specific patient pursuant to a valid prescription, and outlines the information that should be on the label of any drug compounded or repackaged by an outsourcing facility. The Board of Registration in Pharmacy shall enforce all provisions of this Act.

SECTION 1 defines “Compounded Medication,” “Retail Pharmacy,” and “Resale.”

SECTION 2 prohibits retail pharmacies from reselling compounded medications, ensures compounded medications prepared by a retail pharmacy are only dispensed to the patient for whom they were compounded pursuant to a valid prescription, and directs the Board of Registration in Pharmacy to determine disciplinary actions against retail pharmacies that violate this section.

SECTION 3 Prohibits the resale of compounded drugs labeled “not for resale” in accordance with section (2)(c)(ix), outlines the information that should be included on the label of any drug compounded or repackaged by an outsourcing facility, and restricts the sale or transfer of compounded or repackaged drugs to only the outsourcing facility responsible for the compounding or repackaging of said drug.

SECTION 4 Directs the Board of Registration in Pharmacy to enforce all provisions of this Act.

SECTION 5 is a severability clause that enables the rest of this Act to remain in effect if one provision is determined to be legally invalid.